Hydroxyamine

Hydroxyamine

SCHEMBL8224643

CCCC[C@@H]([C@@H](C)C(=O)O)S(=O)(=O)c1ccc(OC)c(OC)c1.NO

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 10/20 0.50
PDE4B Q07343 10/20 0.50
PDE4C Q08493 10/20 0.50
PDE4D Q08499 10/20 0.50
MAPK1 P28482 2/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.43
MMP9 P14780 1/20 0.42
MMP13 P45452 1/20 0.42
POLB P06746 1/20 0.41
TSHR P16473 1/20 0.41
MMP1 P03956 3/20 0.41
MMP2 P08253 3/20 0.41
MMP3 P08254 3/20 0.41
LDHA P00338 1/20 0.39
HIF1A Q16665 1/20 0.39
EPAS1 Q99814 1/20 0.39
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydroxyamine SCHEMBL8212182 0.86 PDE4A (0.62) PDE4APDE4BPDE4CPDE4DMMP1
SCHEMBL7368204 0.81 PDE4A (0.45) PDE4APDE4BPDE4CPDE4DMAPK1
Hydroxyamine SCHEMBL7553741 0.80 MMP9 (0.52) PDE4APDE4BPDE4CPDE4DMAPK1
Hydroxyamine SCHEMBL8224639 0.80 PDE4A (0.46) PDE4APDE4BPDE4CPDE4DMAPK1
SCHEMBL7207041 0.78 MMP1 (0.61) PDE4APDE4BPDE4CPDE4DMMP9
SCHEMBL27624855 0.77 PDE4A (0.56) PDE4APDE4BPDE4CPDE4DMAPK1
SCHEMBL8212188 0.76 PDE4A (0.60) PDE4APDE4BPDE4CPDE4DMMP1
SCHEMBL8224640 0.74 PDE4A (0.45) PDE4APDE4BPDE4CPDE4DMAPK1
SCHEMBL27624889 0.74 PDE4A (0.61) PDE4APDE4BPDE4CPDE4DMMP1
SCHEMBL27624819 0.74 PDE4A (0.53) PDE4APDE4BPDE4CPDE4DMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6057369-A USE IN THE TREATMENT OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY WHICH ARE CAPABLE OF BEING MODULATED BY INHIBITING A MATRIX METALLOPROTEINASE (MMP), TUMOR NECROSIS FACTOR (TNF) OR CYCLIC AMP RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 2000-05-02 US claimed